Lomustine and Bevacizumab in Progressive Glioblastoma

2017962 citationsJournal Articlebronze Open Access

Authors

Wolfgang Wick · University Hospital Heidelberg

Thierry Gorlia · European Organisation for Research and Treatment of Cancer

Martin Bendszus · German Cancer Research Center

Martin Taphoorn · Medisch Centrum Haaglanden

Felix Sahm · Heidelberg University

Inga Harting · University Hospital Heidelberg

Alba A. Brandes

Abstract

Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann-La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939 ; Eudra-CT number, 2010-023218-30 .).

Topics & Keywords

Glioma Diagnosis and Treatment Brain Metastases and Treatment Nanoplatforms for cancer theranostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 20, pp. 1954-1963

DOI: 10.1056/nejmoa1707358

Field-Weighted Citation Impact: 44.86